ArticleNPJ precision oncology2025
Exploring drug resistance via intercellular crosstalk using spatial transcriptomics in high-grade serous ovarian carcinoma.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Benchmarking copy number alteration inference methods for spatial transcriptomics.Nature communications · 2026Article
- HAMNO and CGK733 as BRCAness-driven candidates exhibit synthetic lethality with olaparib in BRCA-proficient ovarian cancer.NPJ precision oncology · 2026Article
- Development and validation of a multimodal AI-agent system for prognosis analysis of bladder urothelial carcinoma.NPJ precision oncology · 2026Article
- Deep spatial transcriptomic profiling of ovarian clear cell carcinoma in the real-world setting.Journal of ovarian research · 2026Article
- Multimodal AI in high-grade serous ovarian cancer: integrated prediction and clinical decision-making.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Poly(ADP-ribose) polymerase inhibitors (PARPis) have improved the prognosis of patients with high-grade serous ovarian carcinoma (HGSOC). However, PARPis are not effective for all HGSOC patients. Spatial transcriptomics is a powerful tool for characterizing the tumor microenvironment. We used Visium to analyze eight tumor samples from HGSOC patients with clinical information on PARPi sensitivity. Two complementary analyses were performed: an integrated analysis across all samples, without considering spatial information, and an analysis with spatial information within each sample. Both approaches indicated that midkine (MDK) signaling is involved in PARPi resistance. Furthermore, we identified receptors that enhance MDK signaling in cancer cells. To assess the generalizability of this finding, we deconvolved bulk RNA-sequencing data using single-cell RNA-sequencing data as a reference to examine the relationship between receptor expression levels and overall survival (OS). This analysis revealed that high SDC4 expression in cancer cells is associated with poor OS in HGSOC patients.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.